Subtle differences identified in brains of people with schizophrenia
Wolfgang Omlor, a study co-author and psychiatrist from the University of Zurich in Switzerland, tells Popular Science that 'while schizophrenia may have its own mechanisms shaping brain structure and function, these processes remain far from fully understood.'
To identify trends in physical features common to the brains of people with schizophrenia, Omlor and his team combed through data from the global Enhancing Neuroimaging Genetics Through Meta-Analysis (ENIGMA) database covering 6,037 people. They saw two potential features: an increased uniformity of folding patterns in a part of the brain called the right caudal anterior cingulate region, and an increased variability in the thickness of the cerebral cortex.
An immediate question is whether these features could contribute to causing schizophrenia, or whether they're caused by the condition. Similarly, it's not clear whether these features are innate, or develop over the course of a person's life. Omlor explains that because this study is 'comparing individuals already diagnosed with schizophrenia to controls,' it can't address the question of causation.
As far as whether these features are something with which a person is born, or whether they develop over the course of life, he says, 'It's likely a combination of both. Some features may be present from early development, while others can emerge later, influenced by factors like medication or chronic stress that reshape the brain through neuroplasticity.'
According to Omlor, cortical folding appears to fall into the category of features present from early development and is mostly established before birth and into early childhood. However, schizophrenia itself tends to manifest in late adolescence/early adulthood. This raises the possibility that these folding patterns represent some sort of predisposition to schizophrenia; whether or not this results in the onset of the actual condition, however, will depend on any number of other factors.
The folding of cerebral tissue is one of the brain's most distinctive features. In general, 'folding increases the brain's surface area in limited space and is thought to influence how neurons connect,' Omlor says. Subtle differences in the nature of the way that brain tissue is folded are also a feature of other conditions, although it's difficult to identify what exact effect such differences have.
'Some neurodevelopmental conditions (e.g., autism) also show altered cortical folding,' he says. 'The implications of such differences aren't fully understood, but the more uniform folding in schizophrenia's anterior cingulate could point to a more constrained developmental process in that region.'
Exactly how these folding patterns might interact with the development and nature of the condition remains an open question, but Omlor theorizes that 'the uniform folding patterns may reflect a less flexible interplay between genes and environment at these earlier stages [of development].'
It certainly seems notable that the folds manifest in the right caudal anterior cingulate region, a part of the brain that integrates cognitive and emotional processes. However, a single role should not be given part of the brain.
'Brain regions generally work together in complex networks.So while we do see more uniform folding [in the right caudal anterior cingulate region] in schizophrenia, it's best not to think of [that region] as solely 'responsible' for any single task,' he says.'Rather, it's part of a broader circuit linking thought and emotion.'
The study's second finding is a 'greater variability in cortical thickness' in individuals with schizophrenia. As an example of how nothing related to the brain is ever simple, this isn't merely a question of people with schizophrenia having 'bigger' or 'smaller' cerebral cortices. Instead, one person's cortex might be thinner in some parts and thicker in others, while another might be just the opposite—so even though those two people's cortices might have the same overall volume, their internal make-up might be quite different. In people with schizophrenia, there is a broader spread of such variation in thickness.
The subtleties involved here reflect the fact that the brain's dizzying complexity means it's rarely possible to draw simple conclusions. Even in this case, where a basic interpretation might be that schizophrenia is linked to the volume of the cerebral cortex, the answer is not that straightforward.
'Greater variability of cortical thickness in schizophrenia reflects a broader range beyond a 'more' or 'less' pattern, underscoring the disorder's complexity,' says Omlor.
However, it does appear possible to correlate these differences with the myriad ways in which schizophrenia presents.
'We also found that variations in specific brain regions correlate with schizophrenia symptom domains, suggesting these structural differences mirror the diverse presentations of the condition,' Omlor says.
Ultimately, one key takeaway from this study is that the way in which schizophrenia presents in a person is as unique as that person themselves. Similarly, it appears that there's no single way in which schizophrenia can be reflected in a person's brain. If anything, there's perhaps a set of regions in which the condition manifests, but the ways in which it can do so appear to be many and varied.
Approaching schizophrenia in this individualistic manner isn't merely an abstract consideration. Instead, a better understanding of how and why the condition varies from person to person could 'guide more individualized precision-medicine efforts… by recognizing these differences early on, clinicians and researchers can work toward treatments better suited to each person's unique profile,' according to Omlor.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
2 days ago
- Fox News
Trump administration considers reclassifying marijuana
Fox News senior medical analyst Dr. Marc Siegel joins 'Fox News @ Night' to discuss the possible reclassification and the early warning signs for colon cancer.


Business Wire
3 days ago
- Business Wire
Newron Begins Enrollment in Pivotal Phase III
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that following the completion of a 42 day-screening period and the review of the patients by the Independent Eligibility Committee, it has successfully randomized the first patients in its pivotal ENIGMA-TRS 1 Phase III development program. ENIGMA-TRS 1 will evaluate evenamide as an add-on therapy to current antipsychotics, including clozapine, in patients with treatment-resistant schizophrenia (TRS). Today's announcement marks an important milestone for the clinical advancement of evenamide for treatment-resistant schizophrenia patients who urgently need more effective therapeutic options. Share 'Today's announcement marks an important milestone for the clinical advancement of evenamide for treatment-resistant schizophrenia patients who urgently need more effective therapeutic options,' said Ravi Anand, CMO, Newron Pharmaceuticals. 'We look forward to advancing evenamide through this pivotal Phase III study and delivering an important benefit to patients in need.' ENIGMA-TRS 1 is an international, 52-week, randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics (SGAs), including clozapine, need to meet Treatment Response and Resistance Psychosis (TRRIP) international consensus criteria for TRS. ENIGMA-TRS 1 will enroll at least 600 patients at study centers in Europe, Asia, Latin America and Canada. Prior to randomization, patients undergo a 42-day screening period, during which their TRS diagnosis, antipsychotic plasma levels (background medication), and conformance to protocol selection criteria will be evaluated by an Independent Eligibility Assessment Committee (IEAC) of three leading international schizophrenia experts. The primary assessment of efficacy and safety will be performed 12 weeks after randomization to treatment. The study will continue double-blind and placebo-controlled until the 52-week time point. The 12-week results from the study are expected in Q4 2026. Results from previous Phase II (study 014/015) and Phase III (study 008A) studies have demonstrated evenamide's significant and increasing efficacy as an add-on therapy on multiple measures of psychopathology in patients with TRS and inadequate responders, respectively. These results also confirmed a favorable safety and tolerability profile, adding to the growing evidence that evenamide's glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who are not benefiting from current antipsychotic treatments. ENIGMA-TRS 2, the second study of Newron's pivotal Phase III ENIGMA-TRS program, has been approved by the US Food and Drug Administration (FDA), and will be performed at centers in the US and selected additional countries. It will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase III study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide. Patients will meet selection criteria and be reviewed by the above-mentioned IEAC. The analysis for determination of efficacy and safety will be performed after patients complete 12 weeks of participation in the trial. US investigational centers are expected to initiate the study by October 2025. About schizophrenia Approximately 25 million people worldwide are affected by schizophrenia. Despite more than 60 different types of atypical and typical antipsychotics used to treat schizophrenia globally, a considerable number of patients remain severely ill or resistant to treatment. Overall, 30-50% of patients do not respond to the available medications and are defined as treatment resistant. In addition to the patients with treatment-resistant schizophrenia (TRS), another 20-30% are described as 'poor responders to antipsychotic medication', even if not meeting the criteria for TRS. New findings indicate that patients with TRS have abnormalities in the glutamatergic system, but not in dopaminergic transmission, so there is a significant unmet medical need for treatments with a glutamatergic mechanism of action, efficacious both in TRS patients and in those who are poor responders to the current treatments. About evenamide Evenamide is the first new chemical entity that has demonstrated significant benefits in this difficult-to-treat patient population, as seen in the potentially pivotal Phase III study 008A trial, as an add-on treatment to second generation antipsychotics including clozapine, in 291 poorly responding patients with chronic schizophrenia. The primary endpoint, the Positive and Negative Syndrome Scale (PANSS) 1, and the key secondary endpoint, the Clinical Global Impressions Scale – Severity (CGI-S), were met and showed statistical significance compared to placebo. Importantly, evenamide treatment was associated with statistically significant increases in the proportion of patients who experienced 'clinically meaningful benefit' on the outcome variables. Evenamide was extremely well tolerated, without any of the usual side effects of available antipsychotics. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson's disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as 'will', 'anticipate', 'estimate', 'expect', 'project', 'intend', 'plan', 'believe', 'target', and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. 1 Positive and Negative Syndrome Scale (PANSS) is widely used in clinical trials of schizophrenia and is considered the 'gold standard' for assessment of antipsychotic treatment efficacy (Innvo Clin Neurosci, 2017:


Medscape
4 days ago
- Medscape
Coronary Sinus Reducer Shows Promise, With Caveats
The coronary sinus reducer, an hourglass-shaped stent that narrows the coronary sinus to increase coronary sinus pressure, has shown some promise in treating patients with refractory angina. But a meta-analysis published today in JACC: Cardiovascular Interventions found the benefits of the intervention are likely smaller than those early studies predicted. 'There have been lots of unblinded single-arm studies [of the procedure] but only three randomized controlled trials, so we wanted to look at the different effect sizes to better understand the overall potential efficacy,' said Rasha Al-Lamee, MD, a cardiologist at the National Heart and Lung Institute, part of Imperial College London, London, England, who led the meta-analysis. Al-Lamee and her colleagues looked at data from a combined total of 180 patients in the three trials, as well as 13 single-arm studies with 668 total patients. They found the coronary sinus procedure to be safe, with a success rate of 98.3%. But while both the single-arm and the controlled trials demonstrated improvements in symptoms of angina, the effect size was much smaller in the controlled trials. In the more rigorous trials, 26% of patients experienced at least a one-class improvement and 17% had at least a two-class improvement on the Canadian Cardiovascular Society classification of angina. Those figures were about one third of the gains reported in the single-arm trials. What's more, the randomized controlled trials found no evidence of benefit based on continuous measurements such as the Seattle Angina Questionnaire. Nor did they find improvements in objective measures such as myocardial perfusion associated with the intervention. Deepak Bhatt, MD, a cardiologist at the Icahn School of Medicine at Mount Sinai in New York City, who co-wrote an editorial accompanying the journal article, said more treatment options are needed for patients with refractory angina, who have often exhausted all other medical therapies and surgical procedures. But while coronary sinus reduction shows promise, the meta-analysis demonstrates why more, and larger, trials will be needed before clinicians can use it more broadly. 'It's not an inexpensive procedure, so we want substantial, objectively quantified evidence that it helps patients,' he told Medscape Medical News . 'History is littered with examples of things we were convinced worked but really didn't.' Percutaneous laser therapy, for example, seemed to show benefits for refractory angina at first, but more rigorous randomized trials found no benefit from the procedure, he said. The coronary sinus reducer device is already approved in the UK and Europe and its use is on the rise there, said Al-Lamee, but it has not yet been approved in the US. The ongoing COSIRA-II trial, with an estimated enrollment of 380 patients, should be well-powered enough to provide definitive results and support US approval, she said. Should COSIRA-II show definite benefit, she added, the device may become more of a frontline treatment, used before riskier revascularization options. 'Why have a redo of coronary artery bypass surgery if you have a device that is safe and effective?' she said. Al-Lamee had received consulting and speaker fees from Shockwave Medical, which makes the CSR device. Bhatt reported no relevant financial conflicts.